Therefore, considering that patients requiring EPO treatment are often susceptible to osteoporosis, it is crucial to administer the lowest effective EPO dose to mitigate the adverse consequences of osteoporosis exacerbation. The gene discussed is EPO; the disease is osteoporosis.